Prolactin-Induced Protein (PIP) Regulates Proliferation of Luminal A Type Breast Cancer Cells in an Estrogen-Independent Manner

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Baniwal, Sanjeev K ^a   Chimge, Nyam Osor ^a   Jordan, V Craig ^b   Tripathy, Debu ^a   Frenkel, Baruch ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; EPHRIN B3; ESTROGEN; FIBRONECTIN; FOCAL ADHESION KINASE; HEMATOPOIETIC CELL KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROLACTIN INDUCED PROTEIN; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN KINASE FYN; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE 1; TAMOXIFEN; UNCLASSIFIED DRUG; CARRIER PROTEIN; GLYCOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PIP PROTEIN, HUMAN; TRANSCRIPTOME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL ADHESION; CELL PROLIFERATION; CELL STRAIN T47D; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GROWTH REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STRESS FIBER; BREAST TUMOR; CLASSIFICATION; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

MAMMALIA;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSKELETON; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ESTROGENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HEK293 CELLS; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR PROTEIN-TYROSINE KINASES; STRESS FIBERS; TAMOXIFEN; TRANSCRIPTOME;

EID: 84878638627     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062361     Document Type: Article

References (36)

1. Clark JW, Snell L, Shiu RP, Orr FW, Maitre N, et al. (1999) The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. Br J Cancer 81: 1002-1008.
2. Frendo JL, Xiao G, Fuchs S, Franceschi RT, Karsenty G, et al. (1998) Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression in vivo. J Biol Chem 273: 30509-30516.
3. Naderi A, Meyer M, (2012) Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Res 14: R111.
4. Murphy LC, Tsuyuki D, Myal Y, Shiu RP, (1987) Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). Regulation of PIP gene expression in the human breast cancer cell line, T-47D. J Biol Chem 262: 15236-15241.
5. Shiu RP, Iwasiow BM, (1985) Prolactin-inducible proteins in human breast cancer cells. J Biol Chem 260: 11307-11313.
6. Chalbos D, Haagensen D, Parish T, Rochefort H, (1987) Identification and androgen regulation of two proteins released by T47D human breast cancer cells. Cancer Res 47: 2787-2792.
7. Haagensen DE Jr, Dilley WG, Mazoujian G, Wells SA Jr, (1990) Review of GCDFP-15. An apocrine marker protein. Ann N Y Acad Sci 586: 161-173.
8. Baniwal SK, Little GH, Chimge NO, Frenkel B Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 227: 2276-2282.
9. Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, et al. (2009) Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 23: 1203-1214.
10. Cassoni P, Sapino A, Haagensen DE, Naldoni C, Bussolati G, (1995) Mitogenic effect of the 15-kDa gross cystic disease fluid protein (GCDFP-15) on breast-cancer cell lines and on immortal mammary cells. Int J Cancer 60: 216-220.
11. Caputo E, Manco G, Mandrich L, Guardiola J, (2000) A novel aspartyl proteinase from apocrine epithelia and breast tumors. J Biol Chem 275: 7935-7941.
12. Murphy CS, Meisner LF, Wu SQ, Jordan VC, (1989) Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. Eur J Cancer Clin Oncol 25: 1777-1788.
13. Park WC, Liu H, Macgregor Schafer J, Jordan VC, (2005) Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells. Int J Oncol 27: 1459-1466.
14. Network TCGA, (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
16. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
17. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214.
18. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413.
19. Lee DM, Chang SJ, Park CG, Kim MW, Lim GH, et al. (2005) [Effects of tamoxifen on the voltage-dependent ionic currents in mouse colonic smooth muscle cells]. Korean J Gastroenterol 46: 388-395.
20. Holliday DL, Speirs V, (2011) Choosing the right cell line for breast cancer research. Breast Cancer Res 13: 215.
21. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
22. Bouchard C, Marquardt J, Bras A, Medema RH, Eilers M, (2004) Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. Embo J 23: 2830-2840.
23. Boureux A, Furstoss O, Simon V, Roche S, (2005) Abl tyrosine kinase regulates a Rac/JNK and a Rac/Nox pathway for DNA synthesis and Myc expression induced by growth factors. J Cell Sci 118: 3717-3726.
24. Graf T, (1992) Myb: a transcriptional activator linking proliferation and differentiation in hematopoietic cells. Curr Opin Genet Dev 2: 249-255.
25. Treisman JE, Follette PJ, O'Farrell PH, Rubin GM, (1995) Cell proliferation and DNA replication defects in a Drosophila MCM2 mutant. Genes Dev 9: 1709-1715.
26. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, et al. (2001) The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414: 457-462.
27. Assoian RK, Schwartz MA, (2001) Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 11: 48-53.
28. Liu S, Xu SW, Kennedy L, Pala D, Chen Y, et al. (2007) FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol Biol Cell 18: 2169-2178.
29. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF, (2008) Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 118: 3943-3953.
30. Boudot A, Kerdivel G, Habauzit D, Eeckhoute J, Le Dily F, et al. (2011) Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS One 6: e20898.
31. Ghosh MG, Thompson DA, Weigel RJ, (2000) PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res 60: 6367-6375.
32. Kim J, Petz LN, Ziegler YS, Wood JR, Potthoff SJ, et al. (2000) Regulation of the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 74: 157-168.
33. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639.
34. Dejardin L, Gol-Winkler R, Collette J, Delvenne C, Carlisi I, et al. (1991) Stimulatory effect of oestradiol-17 beta and tamoxifen on gross cystic disease fluid protein 15,000 production and mRNA levels in T47D human breast cancer cells. J Mol Endocrinol 7: 105-112.
35. Haagensen DE, Stewart P, Dilley WG, Wells SA, (1992) Secretion of breast gross cystic disease fluid proteins by T47D breast cancer cells in culture - modulation by steroid hormones. Breast Cancer Res Treat 23: 77-86.
36. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.